Exicure
XCUR

$3.82

66.81%

Market Cap: $6.61M

About: Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Employees: 5

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1.12% less ownership

Funds ownership: 6.72% [Q1] → 5.6% (-1.12%) [Q2]

21% less funds holding

Funds holding: 19 [Q1] → 15 (-4) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

54% less capital invested

Capital invested by funds: $339K [Q1] → $155K (-$185K) [Q2]

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for XCUR.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about XCUR published over the past 30 days

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“Panel”) granted an extension to continue the Company's listing subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 14, 2024. The Company is diligently working to timely satisfy the terms of the Panel's requests and to ensure.

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation.

Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Tuesday, August 27, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28, 2024 under the new CUSIP number 30205M 309. Exicure's common stock.

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting.

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting.

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Reports Second Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2024 Financial Results.

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics.

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Receives Positive Listing Determination from Nasdaq.

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Why Is Exicure (XCUR) Stock Down 27% Today?

Exicure (NASDAQ: XCUR ) stock is dropping on Monday after the prior early-stage pharmaceutical company's shares underwent a rally on Friday. That rally resulted in shares of XCUR stock rising 76% higher during normal trading hours.

Why Is Exicure (XCUR) Stock Down 27% Today?

Exicure, Inc. Reports First Quarter 2024 Financial Results

CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. First Quarter 2024 Finan.

Exicure, Inc. Reports First Quarter 2024 Financial Results

See News Rankings